TY - JOUR
T1 - Low-dose or -number of BCG in non-muscle invasive bladder cancer
T2 - updated systematic review and meta-analysis
AU - Kawada, Tatsushi
AU - Yanagisawa, Takafumi
AU - Bekku, Kensuke
AU - Laukhtina, Ekaterina
AU - Deimling, Markus Von
AU - Majdoub, Mohammed
AU - Chlosta, Marcin
AU - Pradere, Benjamin
AU - Babjuk, Marko
AU - Gontero, Paolo
AU - Moschini, Marco
AU - Araki, Motoo
AU - Shariat, Shahrokh F.
N1 - Publisher Copyright:
© 2023 Future Medicine Ltd.
PY - 2023/8/1
Y1 - 2023/8/1
N2 - Aim: We aimed to review the evidence of reducing the dose or number of BCG instillations in non-muscle invasive bladder cancer (NMIBC) patients. Material & methods: A literature search was done according to Preferred Reporting Items for Meta-Analyses statement. Results: Overall, 15 and 13 studies were eligible for qualitative and quantitative synthesis, respectively. In patients with NMIBC, lowering either the dose or number of BCG instillations increases the risk of recurrence, but not the risk of progression. Lowering the dose of BCG decreases the risk of adverse events compared with standard-dose BCG. Conclusion: Standard-dose and -number of BCG is preferred for NMIBC patients based on oncologic efficacy; however, low-dose BCG could be considered in selected patients who suffer from significant adverse events. Plain language summary Doctors use a medicine called BCG to treat a kind of bladder cancer that hasn't spread to other parts of the body. But because there isn't enough of this medicine, scientists are looking at giving smaller amounts. They found that smaller amounts of the medicine have fewer side effects, but they also found that they might not work as well to stop the cancer from coming back. So, the regular amount of BCG is still the best option for most patients, but smaller amounts might be okay for some people who are worried about side effects. However, more research is needed to make sure it's safe and effective.
AB - Aim: We aimed to review the evidence of reducing the dose or number of BCG instillations in non-muscle invasive bladder cancer (NMIBC) patients. Material & methods: A literature search was done according to Preferred Reporting Items for Meta-Analyses statement. Results: Overall, 15 and 13 studies were eligible for qualitative and quantitative synthesis, respectively. In patients with NMIBC, lowering either the dose or number of BCG instillations increases the risk of recurrence, but not the risk of progression. Lowering the dose of BCG decreases the risk of adverse events compared with standard-dose BCG. Conclusion: Standard-dose and -number of BCG is preferred for NMIBC patients based on oncologic efficacy; however, low-dose BCG could be considered in selected patients who suffer from significant adverse events. Plain language summary Doctors use a medicine called BCG to treat a kind of bladder cancer that hasn't spread to other parts of the body. But because there isn't enough of this medicine, scientists are looking at giving smaller amounts. They found that smaller amounts of the medicine have fewer side effects, but they also found that they might not work as well to stop the cancer from coming back. So, the regular amount of BCG is still the best option for most patients, but smaller amounts might be okay for some people who are worried about side effects. However, more research is needed to make sure it's safe and effective.
KW - BCG
KW - NMIBC
KW - instillation
KW - intravesical
KW - non-muscle invasive bladder cancer
UR - http://www.scopus.com/inward/record.url?scp=85164626036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164626036&partnerID=8YFLogxK
U2 - 10.2217/imt-2022-0309
DO - 10.2217/imt-2022-0309
M3 - Review article
C2 - 37409426
AN - SCOPUS:85164626036
SN - 1750-743X
VL - 15
SP - 933
EP - 943
JO - Immunotherapy
JF - Immunotherapy
IS - 12
ER -
